Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 8/20 | 0.33 |
| ▸ | PPARG | P37231 | 8/20 | 0.33 |
| ▸ | RARG | P13631 | 7/20 | 0.33 |
| ▸ | HMGCR | P04035 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857191 | 0.85 | RXRA (0.42) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL4858958 | 0.82 | GABRA1 (0.41) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL4852964 | 0.81 | RXRA (0.46) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL19815666 | 0.81 | — | — | |
| SCHEMBL4860363 | 0.80 | RXRA (0.46) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL4852194 | 0.80 | RXRA (0.46) | GABRA1GABRB2FABP3FABP4RXRA | |
| SCHEMBL4862597 | 0.79 | RARB (0.43) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL4861540 | 0.79 | RXRA (0.47) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL11109627 | 0.75 | GABRA1 (0.43) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL21483559 | 0.71 | SCN4A (0.36) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090860-A1 | Retinoid x receptor modulators | GARDINIER KEVIN M | 2008-04-17 | — | — | US | disclosed |
| US-7348359-B2 | Retinoid X receptor modulators | ELI LILLY AND COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1373240-B1 | RETINOID X RECEPTOR MODULATORS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040167160-A1 | Retinoid x receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| EP-1373240-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002071827-A2 | RETINOID X RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167160-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | GABRA1 344/4885GABRB2 816/4885FABP3 941/4885 |
| US-20080090860-A1 | Retinoid x receptor modulators | RXRA, RXRG, RXRB | GABRA1 337/4885GABRB2 884/4885FABP3 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.